

Lombard Medical, Inc.  
Form SC 13D/A  
September 15, 2016

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

SCHEDULE 13D/A  
(Amendment No. 2)

UNDER THE SECURITIES ACT OF 1934

Lombard Medical, Inc.  
(Name of Issuer)

Ordinary Shares, par value \$0.01 per share  
(Title and Class of Securities)

KYG555981094  
(CUSIP Number)

Nancy Tomassone  
Invesco Ltd.  
1555 Peachtree Street, N.E., Suite 1800  
Atlanta, Georgia 30309  
Telephone number: (404) 479-2926  
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

September 15, 2016  
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box .

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on following pages)  
(Page of 5 Pages)



- 1 NAME OF REPORTING PERSONS  
 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
- Invesco Ltd.  
 IRS # 980557567
- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
- (b)
- 3 SEC USE ONLY
4. SOURCE OF FUNDS  
 OO
- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
- PURSUANT TO ITEMS 2(d) or 2(e)
- 6 CITIZENSHIP OR PLACE OF ORGANIZATION  
 Bermuda
- |                  |    |                          |
|------------------|----|--------------------------|
|                  | 7  | SOLE VOTING POWER        |
|                  |    | 6,317,851                |
| NUMBER OF SHARES | 8  | SHARED VOTING POWER      |
| BENEFICIALLY     |    | 0                        |
| OWNED BY         | 9  | SOLE DISPOSITIVE POWER   |
| EACH REPORTING   |    | 6,317,851                |
| PERSON WITH      | 10 | SHARED DISPOSITIVE POWER |
|                  |    | 0                        |
- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
 6,317,851
- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
 31.8%
- 14 TYPE OF REPORTING PERSON  
 HC, IA

CUSIP  
No. KYG555981094

Schedule 13D

Page of [INSERT PAGE  
NUMBER] Pages

Item 1. Security and Issuer.

This Schedule 13D/A (this “Statement”) relates to the ordinary shares, par value \$0.01 per share (the “Ordinary Shares”), of Lombard Medical, Inc. (the “Issuer”). The Issuer’s principal executive offices are located at Lombard Medical House, 4 Trident Park, Didcot, Oxfordshire OX11 7HJ, United Kingdom.

Item 2. Identity and Background.

The person filing this statement is Invesco Ltd., a Bermuda corporation (the “Reporting Person”). The principal business address of the Reporting Person is 1555 Peachtree Street N.E., Atlanta, Georgia 30309. The Reporting Person is the parent company of Invesco UK Limited, which is the parent company of Invesco Asset Management Limited, which is the manager of a number of funds and accounts.

The Reporting Person, through its various subsidiaries, is primarily engaged in the business of providing investment management services to institutional and individual investors worldwide. This statement on Schedule 13D is being filed by the Reporting Person on behalf of itself.

Neither the Reporting Person, nor any of its directors, executive officers or controlling persons has, during the past five years, (a) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors), or (b) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting, or mandating activities subject to, Federal or State securities laws or a finding of any violation with respect to such laws.

Item 3. Source and Amount of Funds or Other Consideration.

Historical purchases of the Ordinary Shares by the Reporting Person or its subsidiaries were funded by funds or accounts managed by the Reporting Person or its subsidiaries.

Item 4. Purpose of Transaction.

The Reporting Person acquired the Ordinary Shares for investment purposes.

The Reporting Person and its subsidiaries intend to review the investment in the Issuer on a continuing basis and has and will continue to engage in communications with other shareholders of the Issuer, one or more officers of the Issuer and/or one or more members of the board of directors of the Issuer, knowledgeable industry or market observers, members of the Issuer’s board of directors or management of the Issuer or other representatives of the Issuer, or other persons, regarding the Issuer, including but not limited to its operations, strategy, management, capital structure and the strategic alternatives that may be available to the Issuer. The Reporting Person has discussed and will continue to discuss ideas that, if effectuated, may result in any of the following: a sale or transfer of a material amount of the stock or assets of the Issuer and/or changes in the Board of the Issuer.

Except to the extent the foregoing may be deemed a plan or proposal, the Reporting Person has no plans or proposals which relate to, or could result in, any of the matters referred to in paragraphs (a) through (j) of Item 4 of the Schedule 13D. Notwithstanding anything contained herein, the Reporting Person specifically reserves the right to change their

intentions with respect to any or all of the matters referred to in this Statement.

Item 5. Interest in Securities of the Issuer.

In connection with the Issuer's initial public offering (the "IPO"), Invesco Asset Management Limited purchased on behalf of certain funds and accounts advised by Invesco Asset Management Limited 1,951,818 Ordinary Shares at \$11.00 per share. The funds and accounts that purchased the Ordinary Shares and the amount purchased are as follows: Perpetual Income and Growth Investment Trust PLC (56,026 Ordinary Shares), Invesco Perpetual UK Equity Pension Fund (560,264 Ordinary Shares), Invesco Perpetual UK Growth Fund (280,132 Ordinary Shares), Invesco Perpetual UK Strategic Income Fund (700,329 Ordinary Shares), Invesco UK Equity Fund (74,935 Ordinary Shares), Keystone Investment Trust PLC (70,033 Ordinary Shares), and The Shipbuilding Industries Pension Scheme (210,099 Ordinary Shares). The Ordinary Shares were purchased from Jefferies LLC on behalf of the underwriters in connection with the IPO, and the purchases settled on April 30, 2014.

Additionally, on the closing of the IPO, certain funds and accounts advised by Invesco Asset Management Limited received a total of 4,366,032 Ordinary Shares by way of exchange pursuant to a scheme of arrangement described in the Issuer's Final Prospectus dated April 25, 2014. The funds and accounts that received the Ordinary Shares by exchange and the amount received are as follows: Perpetual Income and Growth Investment Trust PLC (1,833,121 Ordinary Shares), Invesco Perpetual Children's Fund (240,594 Ordinary Shares), Invesco Perpetual UK Growth Fund (1,230,688 Ordinary Shares), Invesco Perpetual UK Strategic Income Fund (458,545 Ordinary Shares), Invesco UK Equity Fund (226,387 Ordinary Shares), and Keystone Investment Trust PLC (376,697 Ordinary Shares). As of the date of this Statement, the Reporting Person beneficially owns a total of 6,317,851 Ordinary Shares, which in the aggregate represent 31.8% of the Issuer's Ordinary Shares based on 19,885,964 Ordinary Shares outstanding as of December 31, 2015, disclosed by the Issuer on February 22, 2016.

The Reporting Person and its subsidiaries disclaim beneficial ownership of the securities referred to in this Statement, and the filing of this Statement will not be construed as an admission that the Reporting Person or its subsidiaries are, for the purpose of Schedule 13D or 13G of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the beneficial owners of any securities covered by this Statement.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

None.

Item 7. Material to be Filed As Exhibits.

None.

---

CUSIP  
No. KYG555981094

Schedule 13D/A

Page of [INSERT PAGE  
NUMBER] Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: September 15, 2016

INVESCO LTD.

By: /s/ Nancy Tomassone

Name: Nancy Tomassone

Title: Global Assurance Officer